Neuroendocrine Tumor Program

Contact Information & Referrals

NOLANETS-New Orleans Louisiana Neuroendocrine Tumor Specialists
An affiliation between LSU & Ochsner Medical Center - Kenner

Image Caption 200 West Esplanade, Suite 200
Kenner, LA 70065
504-464-8500
1-866-91-ZEBRA
Fax 504-464-8525

The Neuroendocrine Program at Ochsner Medical Center – Kenner specializes in the diagnosis and management of all forms of neuroendocrine tumors, of which carcinoid are the most common. The program is an affiliation between Louisiana State University Health Science Center and Ochsner Medical Center. Please look to the right to find more information about the Neuroendocrine Tumor Program and the staff.

Image Caption

Read the story of Ochsner patient, Stephen Hooker who was in an online support group for individuals suffering from carcinoid cancer. Mr. Hooker was responding to the question, "Seeking Specialist Treatment - Where do I begin?" - Click Here

What is a Neuroendocrine Tumor?

It is a rare hormone producing tumor that affects neuroendocrine cells and are present throughout the nervous and endocrine systems. Most of the time it is very slow growing and it is often difficult to diagnose. The patient may present with vague symptoms such as flushing, diarrhea, palpitations, cardiac disease or wheezing. Because of the difficulty in diagnosing these tumors, diagnosis is delayed on average of 10 years.

There are many types of neuroendocrine tumors:

  • Carcinoid
  • Insulinomas
  • Adrenal pheochromocytomas
  • Gastrinomas
  • Glucagonomas
  • Ghrelinoma
  • Medullary carcinomas of the thyroid
  • Multiple endocrine neoplasia syndromes
  • Pancreatic endocrine tumors
  • VIPomas (vasoactive intestinal polypeptide tumor)

Where are neuroendocrine tumors located?

Neuroendocrine tumors can originate anywhere in the body. Carcinoid tumors, however, are the most common detected and are usually found in the lungs or GI tract. How successful are the treatments? Neuroendocrine treatment is multi-disciplinary, with local and systemic forms of therapies available. But Ochsner is witnessing more people living beyond 10 years. With new agents on the horizon, it now becomes the challenge to shrink the disease, while continuing to improve the quality of life.